# POC Study to Evaluate the Performance of the AcuVid COVID-19 Rapid Antigen Saliva Test

> **NCT05119530** · — · UNKNOWN · sponsor: **Therma Bright Inc** · enrollment: 300 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DIAGNOSTIC_TEST:** AcuVid COVID-19 Rapid Antigen Saliva Test

## Key facts

- **NCT ID:** NCT05119530
- **Lead sponsor:** Therma Bright Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-06
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05119530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05119530, "POC Study to Evaluate the Performance of the AcuVid COVID-19 Rapid Antigen Saliva Test". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05119530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*